Picture of Eli Lilly and logo

LLY — Eli Lilly and News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes

BRIEF-Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes

- Eli Lilly and Company LLY.N:

  • ELI LILLY: PHASE 2 DATA SHOWED ELORATZP DELIVERED WEIGHT LOSS OF UP TO AVERAGE OF 54.1 LBS (23.3%) AT 48 WEEKS IN ADULTS WITH OBESITY, TYPE 2 DIABETES

  • ELI LILLY: ELORATZP LOWERED A1C BY UP TO AVERAGE OF 2.9%, WITH UP TO 77% OF PARTICIPANTS ACHIEVING NORMAL BLOOD SUGAR LEVELS

  • ELI LILLY: PHASE 3 SURMOUNT-ADOLESCENTS SHOWED ZEPBOUND REDUCED BMI BY AVERAGE OF 21.4% IN ADOLESCENTS AGED 12 TO <18 YEARS WITH OBESITY

Source text: [ID:]

Further company coverage: LLY.N


((Reuters.Briefs@thomsonreuters.com;))

Recent news on Eli Lilly and

See all news